Prognostic value of multimarker analysis in stage III colorectal cancer: One step forward towards an individualized therapy decision

Onkologie

Volumn 28, Issue 8-9, 2005, Pages 399-403

  Grabowski, Patricia ^a   Maaser, Kerstin ^a   Hanski, Christoph ^a   Stein, Harald ^b   Sturm, Isrid ^d   Hopfenmüller, Werner ^c   Dörken, Bernd ^d   Buhr, Heinz Johannes ^d   Zeitz, Martin ^a   Scherübl, Hans ^a,d  

^a Medical Clinic I   (Germany)

^b Institute of Pathology   (Germany)

^c Institute of Medical Statistics   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Apoptosis; Colorectal cancer; Multimarker analysis; Neuroendocrine differentiation

Indexed keywords

BENZODIAZEPINE RECEPTOR; BIOLOGICAL MARKER; PARAFFIN; PROTEIN; PROTEIN BAX; PROTEIN P53; SIALYL LEX PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISCRIMINANT ANALYSIS; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MALE; MATHEMATICAL COMPUTING; MULTIVARIATE ANALYSIS; NEUROSECRETORY CELL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; COLORECTAL NEOPLASMS; DISCRIMINANT ANALYSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 27644463847     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000086514     Document Type: Article

References (31)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ: Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. McLeod HL, Murray GI: Tumour markers of prognosis in colorectal cancer. Br J Cancer 1999;79:191-203.
3. Elsaleh H, Iacopetta B: Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma. Clin Colorectal Cancer 2001;1:104-109.
4. Schelwies K, Sturm I, Grabowski P, Scherübl H, Schindler I, Hermann S, Stein H, Buhr HJ, Riecken EO, Zeitz M, Dörken B, Daniel PT: Analysis of p53/BAX in primary colorectal carcinoma: low BAX protein expression is a negative prognostic factor in UICC stage III tumors. Int J Cancer 2002;99:589-596.
5. Paradiso A, Simone G, Lena MD, Leone B, Vallejo C, Lacava J, Dellapasqua S, Daidone MG, Costa A: Expression of apoptosis-related markers and clinical outcome in patients with advanced colorectal cancer. Br J Cancer 2001;84:651-658.
6. Giatromanolaki A, Sivridis E, Stathopoulos GP, Fountzilas G, Kalofonos HP, Tsamandas A, Vrettou E, Scopa C, Polychronidis A, Simopoulos K, Koukourakis MI: Bax protein expression in colorectal cancer: association with p53, bcl-2 and patterns of relapse. Anticancer Res 2001;21:253-259.
7. Grizzle WE, Manne U, Weiss HL, Jhala N, Talley L: Molecular staging of colorectal cancer in African-American and Caucasian patients using phenotypic expression of p53, Bcl-2, MUC-1 AND p27(kip-1). Int J Cancer 2002;97:403-409.
8. Bhatavdekar JM, Patel DD, Chikhlikar PR, Shah NG, Vora HH, Ghosh N, Trivedi TI: Molecular markers are predictors of recurrence and survival in patients with Dukes B and Dukes C colorectal adenocarcinoma. Dis Colon Rectum 2001;44:523-533.
9. Grabowski P, Schindler I, Anagnostopoulos I, Foss HD, Riecken EO, Mansmann U, Stein H, Berger G, Buhr HJ, Scherübl H: Neuroendocrine differentiation is a relevant prognostic factor in stage III-IV colorectal cancer. Eur J Gastroenterol Hepatol 2001;13:405-411.
10. Maaser K, Höpfner M, Jansen A, Weisinger G, Gavish M, Kozikowski AP, Weizman A, Carayon P, Riecken EO, Zeitz M, Scherübl H: Specific ligands of the peripheral benzodiazepine receptor induce apoptosis and cell cycle arrest in human colorectal cancer cells. Br J Cancer 2001;85:1771-1780.
11. Hardwick M, Fertikh D, Culty M, Li H, Vidic B, Papadopoulos V: Peripheral-type benzodiazepine receptor (PBR) in human breast cancer: correlation of breast cancer cell aggressive phenotype with PBR expression, nuclear localization, and PBR-mediated cell proliferation and nuclear transport of cholesterol. Cancer Res 1999;59:831-842.
12. Venturini I, Zeneroli ML, Corsi L, Avallone R, Farina F, Alho H, Baraldi C, Ferrarese C, Pecora N, Frigo M, Ardizzone G, Arrigo A, Pellicci R, Baraldi M: Up-regulation of peripheral benzodiazepine receptor system in hepatocellular carcinoma. Life Sci 1998;63:1269-1280.
13. Hanski C, Hanski ML, Zimmer T, Ogorek D, Devine P, Riecken EO: Characterization of the major sialyl-Lex-positive mucins present in colon, colon carcinoma, and sera of patients with colorectal cancer. Cancer Res 1995;55:928-933.
14. Takahashi S, Oda T, Hasebe T, Sasaki S, Kinoshita T, Konishi M, Ueda T, Nakahashi C, Ochiai T, Ochiai A: Overexpression of sialyl Lewis x antigen is associated with formation of extratumoral venous invasion and predicts postoperative development of massive hepatic metastasis in cases with pancreatic ductal adenocarcinoma. Pathobiology 2001;69:127-135.
15. Grabowski P, Mann B, Mansmann U, Lovin N, Foss HD, Berger G, Scherübl H, Riecken EO, Buhr HJ, Hanski C: Expression of SIALYL-Le(x) antigen defined by MAb AM-3 is an independent prognostic marker in colorectal carcinoma patients. Int J Cancer 2000;88:281-286.
16. Miyashita T, Reed JC: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995;80:293-299.
17. Maaser K, Grabowski P, Sutter AP, Höpfner M, Foss HD, Stein H, Berger G, Gavish M, Zeitz M, Scherübl H: Overexpression of the peripheral benzodiazepine receptor is a relevant prognostic factor in stage III colorectal cancer. Clin Cancer Res 2002;8:3205-3209.
18. O'Connell JB, Maggard MA, Ko CY: Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004;96:1420-1425.
19. Sturm I, Köhne CH, Wolff G, Petrowsky H, Hillebrand T, Hauptmann S, Lorenz M, Dörken B, Daniel PT: Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases. J Clin Oncol 1999;17:1364-1374.
20. Hanski C, Bornhoeft G, Topf N, Hermann U, Stein H, Riecken EO: Detection of a mucin marker for the adenoma-carcinoma sequence inhuman colonic mucosa by monoclonal antibody AM-3. J Clin Pathol 1990;43:379-384.
21. Lagendijk JH, Mullink H, van Diest PJ, Meijer GA, Meijer CJ: Tracing the origin of adenocarcinomas with unknown primary using immunohistochemistry: differential diagnosis between colonic and ovarian carcinomas as primary sites. Hum Pathol 1998;29:491-497.
22. Lanza G, Gafa R, Santini A, Maestri I, Dubini A, Gilli G, Cavazzini L: Prognostic significance of DNA ploidy in patients with stage II and stage III colon carcinoma: a prospective flow cytometric study. Cancer 1998;82:49-59.
23. Staib L, Link KH, Blatz A, Beger HG: Surgery of colorectal cancer: surgical morbidity and five- and ten-year results in 2400 patients - monoinstitutional experience. World J Surg 2002;26:59-66.
24. Sandforth F, Witzel L, Balzer T, Gutschmidt S, Janicke I, Riecken EO: Identification of patients at high risk for colorectal carcinoma from biopsy studies of the apparently normal colorectal mucosa. A multivariate analysis. Eur J Clin Invest 1991;21:295-302.
25. Yuceyar S, Erturk S, Dirican A, Cengiz A, Saner H: The role of acute-phase reactant proteins, carcinoembryonic antigen and CA 19-9 as a marker in the preoperative staging of colorectal cancer: a prospective clinical study. Int Surg 1996;81:136-139.
26. Han XC, Li JL, Han G: Surgical mortality in patients with malignant obstructive jaundice: a multivariate discriminant analysis. Hepatobiliary Pancreat Dis Int 2003;2:435-440.
27. Sturm I, Petrowsky H, Volz R, Lorenz M, Radetzki S, Hillebrand T, Wolff G, Hauptmann S, Dörken B, Daniel PT: Analysis of p53/BAX/p16(ink4a/CDKN2) in esophageal squamous cell carcinoma: high BAX and p16(ink4a/CDKN2) identifies patients with good prognosis. J Clin Oncol 2001;19:2272-2281.
28. Güner D, Sturm I, Hemmati P, Hermann S, Hauptmann S, Wurm R, Budach V, Dörken B, Lorenz M, Daniel PT: Multigene analysis of Rb pathway and apoptosis control in esophageal squamous cell carcinoma identifies patients with good prognosis. Int J Cancer 2003;103:445-454.
29. Daniel PT, Schulze-Osthoff K, Belka C, Guner D: Guardians of cell death: the Bcl-2 family proteins. Essays Biochem 2003;39:73-88.
30. Schmitt-Graff A, Müller H, Rancso C, Ahnert-Hilger G, John M, Riecken EO, Stein H, Wiedenmann B: Molecules of regulated secretion are differentiation markers of neuroendocrine tumors. Verh Dtsch Ges Pathol 1997;81:157-161.
31. Grabowski P, Schönfelder J, Ahnert-Hilger G, Foss HD, Heine B, Schindler I, Stein H, Berger G, Zeitz M, Scherübl H: Expression of neuroendocrine markers: a signature of human undifferentiated carcinoma of the colon and rectum. Virchows Arch 2002;441:256-263.